Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator. Last year, the clinical-stage biotech said that AbbVie ( ABBV) discontinued further enrollment in an early-stage trial for a combination therapy involving its TLR9 agonist tilsotolimod. 50 per share of Checkmate Fueled by Dupixents 557 million in. Meanwhile, Idera Pharmaceuticals ( NASDAQ: IDRA), another developer of TLR9 agonists, has recorded the best intraday gain since December. In April 2022, the business announced it would acquire Checkmate Pharmaceuticals for around 250 million, enhancing its number of immuno-oncology drugs.An agreement announced to go public via a SPAC merger has also driven the stock higher today. 84O - Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816 Tumour Site. Oncology-focused cell therapy company, Coeptis Therapeutics ( OTCPK:COEP), which recently agreed to acquire Statera Biopharma's ( STAB) TLR5 agonist platform, has reached a two-month high.The announcement has propelled the developers of Toll-like receptor 9 (TLR9) agonists, a drug class used to describe Checkmate’s ( CMPI ) lead asset vidutolimod.The clinical-stage biotech, Checkmate Pharmaceuticals ( NASDAQ: CMPI), has risen more than fourfold in value on Tuesday following its $250 million all-cash deal to be acquired by Regeneron ( REGN). Regeneron has shown there is more to skin cancer drugs than PD-1 inhibitors through its 250 million acquisition of Checkmate Pharmaceuticals and its lead immuno-oncology asset vidutolimod.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |